Latest studies
- Not yet recruitingPHASE3
A Study to Evaluate Effect of AZD6234 in Adult Participants With Type 2 Diabetes Mellitus and Obesity or Overweight
This study is looking at a new medicine, AZD6234, for adults with Type 2 diabetes who are also overweight or have obesity. It aims to see how well it helps with weight loss and how safe it is compared to a dummy medicine.
Obesity or OverweightDiabetes Mellitus, Type 2Taiwan - RecruitingPHASE3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
This study looks at the long-term safety and effectiveness of a cancer drug called pembrolizumab (and related treatments) for people with advanced cancers. It's for patients who are already receiving these treatments in other studies and want to continue.
Solid TumorsHematologic MalignanciesTaiwan - RecruitingPHASE3
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
This study is testing a new drug, neladalkib, for people with a common type of lung cancer (NSCLC) that's ALK-positive. It's comparing neladalkib to a standard treatment, alectinib, to see if neladalkib works better at stopping the cancer from growing.
Non-small Cell Lung CancerAnaplastic Lymphoma Kinase-positiveTaiwan - RecruitingPHASE3
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
This study is testing a new medicine, Pasritamig, for men with advanced prostate cancer that has spread and is no longer responding to hormone treatments. We want to see if Pasritamig helps men live longer compared to a dummy medicine, alongside their usual supportive care.
Metastatic Castration-resistant Prostatic NeoplasmsTaiwan - RecruitingPHASE2, PHASE3
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
This study is for people with a type of lung cancer that has a specific gene change (EGFR mutation) and has not responded to previous treatment. It compares a new medicine called Iza-bren with standard chemotherapy (carboplatin or cisplatin plus pemetrexed) to see which works better.
Non-Small Cell Lung CancerTaiwan - Available
Expanded Access Program of Zidesamtinib (NVL-520) for Patients With Advanced ROS1+ NSCLC or Other ROS1+ Solid Tumors
This program offers a new medicine called zidesamtinib to adult patients in the UK with advanced ROS1-positive lung cancer or other ROS1-positive cancers. It's for those who have tried other treatments, can't join a regular trial, and have few other options available.
Non Small Cell Lung CancerROS1-positive Non-Small Cell Lung Cancer (NSCLC)Taiwan - Active not recruitingPHASE3
A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
This study looks at new drug combinations for advanced liver cancer that has already been treated. It compares atezolizumab with lenvatinib or sorafenib against lenvatinib or sorafenib alone, to see if the combinations work better and are safe.
Unresectable Hepatocellular CarcinomaTaiwan - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
This study is looking at a new combination of treatments, Inavolisib and Phesgo, for HER2-positive breast cancer that has spread. We want to see if this new combination works better and is safe compared to Phesgo alone after initial treatment.
Metastatic Breast CancerTaiwan - Active not recruitingPHASE2
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
This study looks at a drug called entrectinib for different types of advanced cancer. It focuses on cancers with specific genetic changes (NTRK, ROS1, or ALK gene fusions). Researchers want to see if entrectinib can help treat these cancers.
Breast CancerCholangiocarcinomaColorectal CancerHead and Neck NeoplasmsTaiwan - RecruitingPHASE2, PHASE3
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
This study looks at a new drug called adagrasib, on its own and with another drug, pembrolizumab, for people with advanced lung cancer. It's for those with a specific gene change (KRAS G12C) who haven't had treatment yet.
Advanced Non-Small Cell Lung CancerMetastatic Non-Small Cell Lung CancerTaiwan - RecruitingPHASE2
A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer
This study is testing a new combination of medicines for advanced bowel cancer. It aims to see how safe and effective a new drug, telisotuzumab adizutecan, is when given with standard treatments. The study will look at side effects and whether the cancer activity changes.
Metastatic Colorectal CancerTaiwan - RecruitingPHASE3
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
This study is looking at a new treatment called AAA817, combined with standard prostate cancer drugs, for men with advanced prostate cancer. It compares this new combination to existing treatments to see which works best at slowing the cancer's growth.
Prostate CancerTaiwan - RecruitingPHASE2, PHASE3
A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
This study looks at a new drug, Navlimetostat, combined with standard treatments for advanced lung cancer. It compares this combination to standard treatments alone in patients whose cancer has a specific genetic change called an MTAP deletion. The aim is to see if the new combination works better.
Metastatic Non-small Cell Lung Cancer With MTAP DeletionTaiwan - RecruitingPHASE3
A Master Protocol to Investigate Efficacy and Safety of Elecoglipron in Participants With Obesity or Overweight With or Without T2DM
This study is looking into a new medication called Elecoglipron for weight management. It's for adults who are overweight or have obesity, with or without Type 2 diabetes, to see if it helps them lose weight safely when combined with diet and exercise.
Weight ManagementTaiwan - Not yet recruitingPHASE3
A Study of Orforglipron (LY3502970) Compared With Dulaglutide in Pediatric Participants With Type 2 Diabetes
This study is looking at a new medicine called orforglipron for young people aged 10-17 with type 2 diabetes. It compares it with an existing medicine, dulaglutide, to see how well it works and if it's safe. The study lasts about 61 weeks.
Diabetes Mellitus, Type 2Taiwan - RecruitingPHASE2
Study of ABBV-142 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Idiopathic Pulmonary Fibrosis
This study is looking into a new treatment called ABBV-142 for a lung condition called Idiopathic Pulmonary Fibrosis (IPF). It aims to check if the new drug is safe, what side effects it might cause, and if it helps improve the condition compared to a dummy drug.
Idiopathic Pulmonary FibrosisTaiwan - Active not recruitingPHASE3
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
This study is looking at a new drug, epcoritamab, combined with standard treatments for follicular lymphoma, a type of blood cancer. We want to see if this combination is safe and effective in people who haven't been treated for this condition before.
Follicular Lymphoma (FL)Taiwan - RecruitingPHASE2
Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL
This study is testing a new medicine called Surovatamig for adults with certain types of B-cell non-Hodgkin lymphoma that has returned or not responded to previous treatments. It aims to see how well it works and if it's safe.
B-cell Non-Hodgkin LymphomaFollicular Lymphoma (FL)Large B-Cell Lymphoma (LBCL)Taiwan - RecruitingPHASE2
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
This study looks at new treatments for advanced stomach or oesophageal cancer with a specific protein called HER2. We're testing a new drug, trastuzumab deruxtecan, by itself or with other common cancer medicines to see if it's safe and effective.
Gastric CancerTaiwan - Active not recruitingPHASE3
Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer
This study is testing new combinations of medicines (Zimberelimab and Domvanalimab with chemotherapy) against a standard treatment (Pembrolizumab with chemotherapy) for people with advanced non-small cell lung cancer that hasn't been treated yet. We want to see which combination helps people live longer.
Non-small Cell Lung CancerTaiwan - Active not recruitingPHASE2, PHASE3
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
This study is looking at a new medicine called guselkumab for people with ulcerative colitis that isn't well-controlled. We want to see if it helps reduce symptoms and if it's safe to use for those with moderate to severe forms of the condition.
Ulcerative ColitisTaiwan - Active not recruitingPHASE3
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma.
This study looks at a new drug, tafasitamab, alongside standard treatments for follicular lymphoma and marginal zone lymphoma that have come back or not responded well. It aims to see if adding this new drug works better than the usual treatment alone.
Follicular LymphomaMarginal Zone LymphomaTaiwan - Active not recruitingPHASE3
Roll Over StudY for Patients Who Have Completed a Previous Oncology Study With Olaparib
This study is for people with ovarian or breast cancer who are already receiving olaparib in a different study and are still benefiting. It allows them to continue getting their treatment if their current study ends, ensuring they keep receiving a medication that is helping them.
Ovarian CancerBreast CancerTaiwan - Active not recruitingPHASE3
A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
This study looks at a new medicine called sparsentan for IgA nephropathy (IgAN), a kidney disease. It compares sparsentan to a standard treatment (irbesartan) to see if it helps protect kidneys and reduce protein in the urine over about two years.
Immunoglobulin A NephropathyTaiwan - Active not recruitingPHASE3
Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007)
This study compares a new medication, Bomedemstat, with a standard treatment, Hydroxyurea, for people with Essential Thrombocythemia (ET). It wants to see if Bomedemstat works better at controlling ET for those new to treatment.
Essential ThrombocythemiaTaiwan - RecruitingPHASE3
Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
This study is testing a new medicine, cladribine, in pill form for people with a muscle weakening condition called myasthenia gravis. We want to see if it helps and if it's safe compared to a dummy pill. We're also looking at its long-term effects and how the body uses the medicine.
Generalized Myasthenia GravisTaiwan - RecruitingPHASE1, PHASE2
Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia
This study is testing a new medicine, AZD4512, for B-cell Acute Lymphoblastic Leukaemia (B-ALL) in people whose cancer has come back or not responded to other treatments. Researchers want to see if it's safe and how well it works.
B-cell Acute Lymphoblastic Leukemia (B-ALL)Taiwan - Active not recruitingPHASE3
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
This study is for people who have had surgery for bile duct cancer. It's testing a new medicine called rilvegostomig with chemotherapy, to see if it stops the cancer from coming back. It compares the new medicine to a dummy pill.
Biliary Tract CancerTaiwan - Active not recruitingPHASE3
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Crovalimab Versus Eculizumab in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) Currently Treated With Complement Inhibitors
This study compares a new medicine, crovalimab, to an existing one, eculizumab, for people with a rare blood condition called PNH. It's looking at how safe and effective crovalimab is in patients already receiving similar treatments.
Paroxysmal Nocturnal HemoglobinuriaTaiwan - Active not recruitingPHASE3
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
This study looks at a new way to treat a type of leukaemia (blood cancer) called B-cell precursor acute lymphoblastic leukaemia (ALL) in older adults. It compares a drug called Blinatumomab combined with gentler chemotherapy against the usual chemotherapy treatment to see which works best.
Newly Diagnosed Philadelphia (Ph)-Negative B-cell Precursor Acute Lymphoblastic Leukemia (ALL)Taiwan - Active not recruitingPHASE4
Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.
This study helps people with certain cancers or GvHD who are already taking ibrutinib and benefiting from it. It allows them to keep getting the medication if they can't get it commercially and helps researchers learn more about its long-term use.
Lymphoma, B-CellLymphoma, Non-HodgkinLeukemia, B-cellGraft Vs Host DiseaseTaiwan - Active not recruitingPHASE3
Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome
This study looks at a new drug, venetoclax, combined with existing treatment, azacitidine, for adults with a type of blood disorder called higher-risk Myelodysplastic Syndrome (MDS). It aims to see if this combination is safe and effective compared to azacitidine alone.
Myelodysplastic Syndrome (MDS)Taiwan - Active not recruitingPHASE3
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
This study is testing a new medicine, tulisokibart, for people with moderate to severe ulcerative colitis. It aims to see if the medicine can help people feel better and stay in remission, compared to a dummy medicine, both in the short and long term.
Ulcerative ColitisTaiwan - RecruitingPHASE3
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
This study looks at a new medicine, NNC0487-0111, for people with heart failure and obesity. It compares the medicine to a dummy treatment (placebo) to see if it's safe and helps improve heart health.
ObesityHeart FailureTaiwan - Active not recruitingPHASE3
A Study of Belzutifan (MK-6482) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Clear Cell Renal Cell Carcinoma Post Nephrectomy (MK-6482-022)
This study is comparing two treatments, belzutifan plus pembrolizumab, against pembrolizumab alone, for kidney cancer that has been removed. It aims to see if the combination treatment can prevent the cancer from returning.
Carcinoma, Renal CellTaiwan - RecruitingPHASE4
Real-World Effectiveness and Safety of Pegcetacoplan in Patients With C3G or IC-MPG: A Multi-Country Study
This study looks at how well a medicine called pegcetacoplan works and if it's safe for people in the UK with rare kidney diseases like C3G or IC-MPGN. It uses real-life information from patients to help doctors make better decisions about treatment.
C3 Glomerulopathy (C3G)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)Taiwan - Active not recruitingPHASE3
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
This study is looking at new ways to treat a type of breast cancer that doesn't have certain hormone receptors or HER2 protein, called triple-negative or hormone receptor-low/HER2-negative breast cancer. It tests two different treatment plans using new and existing medicines before and after surgery.
Breast CancerTaiwan - Active not recruitingPHASE3
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
This study is looking at a new drug, quizartinib, combined with standard chemotherapy for adults recently diagnosed with a specific type of leukaemia called AML. We want to see if this combination improves treatment outcomes compared to chemotherapy alone.
LeukemiaTaiwan - RecruitingPHASE3
A Clinical Study of Sotatercept (MK-7962) in People With Pulmonary Arterial Hypertension (MK-7962-038)
This study is for people who have already taken part in other studies for a medicine called sotatercept, used to treat Pulmonary Arterial Hypertension (PAH). It aims to check the long-term safety and how well people tolerate sotatercept when taken with their usual PAH treatments.
Pulmonary Arterial HypertensionTaiwan - Active not recruitingPHASE3
Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer
This study is looking at a new combination of medicines, capivasertib and fulvestrant, for women and men with a specific type of advanced breast cancer. It compares this combination to fulvestrant plus a dummy drug to see if it works better.
Locally Advanced (Inoperable) or Metastatic Breast CancerTaiwan - Active not recruitingPHASE1, PHASE2
A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer
This study is looking at new combinations of medicines for HER2-positive breast cancer that has spread. It aims to see how safe and effective these combinations are in patients whose advanced breast cancer has come back or spread.
Metastatic Breast CancerTaiwan - Active not recruitingPHASE2
Efficacy and Safety of GSK4527226 [AL101] in Participants With Early Alzheimer's Disease
This study is testing a new medicine, GSK4527226, for people in the early stages of Alzheimer's disease. Researchers want to see if it's safe and helps improve or slow down symptoms compared to a dummy medicine.
Alzheimer's DiseaseTaiwan - RecruitingPHASE3
A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Compared With Placebo in Adults With Type 2 Diabetes Mellitus and Impaired Renal Function on Background Dapagliflozin
This study is testing a new medicine, Elecoglipron, for adults with type 2 diabetes and kidney problems. It compares Elecoglipron to a dummy pill (placebo) to see if it's safe and effective when taken with other usual diabetes medicines, including dapagliflozin.
Type 2 Diabetes MellitusType 2 Diabetes With Chronic Kidney DiseaseTaiwan - Active not recruitingPHASE3
A Phase III Study to Assess the Effect of AZD0780 on LDL-C in Patients With Clinical ASCVD or at Risk for a First ASCVD Event
This study looks at a new drug, AZD0780, for people with heart disease or who are at risk of it, and who have high 'bad' cholesterol (LDL-C). We want to see if AZD0780 safely lowers this cholesterol.
Cardiovascular DiseaseTaiwan - Active not recruitingPHASE3
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
This study is for people with cancer who are already receiving specific cancer treatments in another study. It allows them to continue their treatment if their original study ends and they can't get the medicine elsewhere. It's about safely extending access to these important cancer drugs.
CancerTaiwan - RecruitingPHASE3
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
This study is looking into a new medication, rilzabrutinib, for adults with a condition called IgG4-related disease. It compares the medication to a dummy pill to see if it's safe and helps control the disease over 52 weeks.
Immunoglobulin G4 Related DiseaseTaiwan - Active not recruitingPHASE3
Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer
This study looks at a new drug, durvalumab, and standard chemotherapy (FLOT) for stomach or food pipe cancer that can be removed by surgery. It aims to see if this combination, given before and after the operation, is safe and effective.
Gastrointestinal NeoplasmsEsophagogastric JunctionTaiwan - RecruitingPHASE3
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
This study looks at a new drug, patritumab deruxtecan, for a certain type of advanced breast cancer. It aims to see if this new treatment helps people live longer or stops cancer from growing compared to standard treatments like chemotherapy.
Breast NeoplasmsTaiwan - RecruitingPHASE3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
This study is testing a new medicine, enicepatide, for people who are overweight or have obesity but do not have type 2 diabetes. It aims to see if the medicine helps with weight loss and if it's safe compared to a dummy medicine.
Obesity or OverweightTaiwan - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
This study is testing a new medication called Tulisokibart for people with moderate to severe Crohn's disease. Researchers want to see if it's safe and effective in reducing symptoms and improving the gut lining. It involves different ways of giving the medicine compared to a dummy treatment.
Crohn's DiseaseTaiwan